<![CDATA[Communicating CAR T Secondary Malignancy Risks in Hematologic Oncology]]>

ConferenceCAR T-cell therapyNegative

AI Analysis

Summary

Dr. Jasmine Zain discussed FDA boxed warning communications regarding secondary malignancy risks associated with CAR T-cell therapy at SOHO 2026 conference.

Importance:2/10

Sentiment:

-0.30

CAR T-cell therapysecondary malignancyFDA boxed warninghematologic oncologypatient communicationSOHO 2026

Related Companies

$DFPH

Read the original article

Published by Cancer Network on September 10, 2026 4:30 PM

Read Original